NCT05126992View on ClinicalTrials.gov

EU Secondary Data Post-Authorisation Safety Study of AZD1222

CompletedOBSERVATIONAL
Enrollment

5,321,930

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions
COVID-19, Vaccine Adverse Events of Special Interest
Interventions
BIOLOGICAL

AZD1222

Covid-19 AstraZeneca Vaccine

Trial Locations (4)

8007

Research Site, Barcelona

46020

Research Site, Valencia

3528 AE

Research Site, Utrecht

SO31 1AA

Research Site, Southampton

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

RTI Health Solutions

OTHER

lead

AstraZeneca

INDUSTRY